Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marchex (MCHX) Cash & Equivalents (2016 - 2025)

Marchex (MCHX) has disclosed Cash & Equivalents for 16 consecutive years, with $9.9 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 22.13% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, down 22.13%, while the annual FY2025 figure was $9.9 million, 22.13% down from the prior year.
  • Cash & Equivalents was $9.9 million for Q4 2025 at Marchex, down from $10.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $28.2 million in Q1 2021, with the low at $9.9 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $17.6 million across 5 years, with a median of $14.4 million in 2023.
  • The largest annual shift saw Cash & Equivalents decreased 10.77% in 2022 before it tumbled 43.1% in 2023.
  • Over 5 years, Cash & Equivalents stood at $27.1 million in 2021, then dropped by 24.41% to $20.5 million in 2022, then dropped by 28.66% to $14.6 million in 2023, then decreased by 12.6% to $12.8 million in 2024, then dropped by 22.13% to $9.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $9.9 million in Q4 2025, $10.3 million in Q3 2025, and $10.5 million in Q2 2025.